Plasma biomarkers of oxidative and AGE-mediated damage of proteins and glycosaminoglycans during healthy ageing: A possible association with ECM metabolism

Mechanisms of Ageing and Development

Volumn 133, Issue 8, 2012, Pages 538-548

  Komosinska Vassev, Katarzyna ^a   Olczyk, Pawel ^a   Winsz Szczotka, Katarzyna ^a   Klimek, Katarzyna ^a   Olczyk, Krystyna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Advanced glycation end products; Antioxidants; Carbonyl groups; Endogenous secretory receptor for advanced glycation end products; Physiological ageing; Thiol groups

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CHONDROITIN SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; PROTEOGLYCAN; THIOL DERIVATIVE;

ADULT; AGED; AGING; ARTICLE; CHILD; FEMALE; HUMAN; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN GLYCOSYLATION; PROTEIN METABOLISM; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; EXTRACELLULAR MATRIX; FEMALE; GLYCOSAMINOGLYCANS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFANT; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84865352202     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2012.07.001     Document Type: Article

References (51)

1. Robert L. Cellular and molecular mechanisms of aging and age related diseases. Pathology Oncology Research 2000, 6:3-9.
2. Bailey A.J. Molecular mechanisms of ageing in connective tissues. Mechanisms of Ageing and Development 2001, 122:735-755.
3. Baynes J.W. The role of AGEs in aging: causation or correlation. Experimental Gerontology 2001, 36:1527-1537.
4. Handel T.M., Johnson Z., Crown S.E., Lau E.K., Sweeney M., Proudfoot A.E. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annual Review of Biochemistry 2005, 74:385-410.
5. Schönherr E., Hauser H.J. Extracellular matrix and cytokines: a functional unit. Developmental Immunology 2000, 7:89-101.
6. Volpi N., Cusmano N., Venturelli T. Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochimica et Biophysica Acta 1995, 1243:49-58.
7. Sames K. The role of proteoglycans and glycosaminoglycans in aging. Hamburg 1994, 103. S. Karger (Ed.).
8. Larking P.W. Total glycosaminoglycans in plasma of adults: effects of age and gender, and relationship to plasma lipids: a preliminary study. Biochemical Medicine and Metabolic Biology 1989, 42:192-197.
9. Komosinska-Vassev K., Winsz-Szczotka K., Kuznik-Trocha K., Olczyk P., Olczyk K. Age-related changes of plasma glycosaminoglycans. Clinical Chemistry and Laboratory Medicine 2008, 46:219-224.
10. Ricciardelli C., Sakko A.J., Stahl J., Tilley W.D., Marshall V.R., Horsfall D.J. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate 2009, 69:761-769.
11. Moseley R., Stewart J.E., Stephens P., Waddington R.J., Thomas D.W. Extracellular matrix metabolites as potential biomarkers of disease activity in wound fluid: lessons learned from other inflammatory diseases?. British Journal of Dermatology 2004, 150:401-413.
12. Yin D., Chen K. The essential mechanisms of ageing: irreparable damage accumulation of biochemical side-reactions. Experimental Gerontology 2005, 40:455-465.
13. Madian A.G., Regnier F.E. Proteomic identification of carbonylated proteins and their oxidation sites. Journal of Proteome Research 2010, 9:3766-3780.
14. Rahbar S., Figarola J.L. Novel inhibitors of advanced glycation endproducts. Archives of Biochemistry and Biophysics 2003, 419:63-79.
15. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions in human disease. International Journal of Biochemistry and Cell Biology 2007, 39:44-84.
16. Pandey K.B., Rizvi S.I. Markers of oxidative stress in erythrocytes and plasma during aging in humans. Oxidative Medicine and Cellular Longevity 2010, 2:2-12.
17. Dröge W. Oxidative stress and ageing: is ageing a cysteine deficiency syndrome?. Philosophical Transactions of the Royal Society B 2005, 360:2355-2372.
18. Kalousova M., Zima T., Tesar V., Dusilova-Sulkova S., Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutation Research 2005, 579:37-46.
19. Nagai R., Mori T., Yamamoto Y., Kaji Y., Yonei Y. Significance of advanced glycation end products in ageing-related disease. Anti-Ageing Medicine 2010, 7:112-119.
20. Sell D.R., Monnier V.M. Molecular basis of arterial stiffening: role of glycation. Gerontology 2012, 10.1159/000334668.
21. Brownlee M. Negative consequences of glycation. Metabolism: Clinical and Experimental 2000, 49:9-13.
22. Crasto C.L., Semba R.D., Sun K., Dalal M., Corsi A.M., Bandinelli S., Guralnik J.M., Ferrucci L. Endogenous secretory receptor for advanced glycation end products is associated with low serum interleukin-1 receptor antagonist and elevated IL-6 in older community-dwelling adults. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2011, 66A:437-443.
23. Uribarri J., Cai W., Peppa M., Goodman S., Ferrucci L., Striker G., Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and ageing. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2007, 62:427-433.
24. Vlassara H., Cai W., Goodman S., Pyzik R., Yong A., Chen X., Zhu L., Neade T., Beeri M., Silverman J.M., Ferrucci L., Tansman L., Striker G.E., Uribarri J. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the anti-inflammatory AGE receptor-1. Journal of Clinical Endocrinology and Metabolism 2009, 94:4483-4491.
25. Olczyk K., Głowacki A., Koźma E.M. Non-insulin dependent diabetes mellitus-associated changes in serum glycosaminoglycans. Pathophysiology 1997, 4:121-129.
26. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Analytical Biochemistry 1973, 54:484-489.
27. Slim G.C., Furneaux R.H., Yorke S.C. A procedure for analysis of glycosaminoglycans mixtures based on digestion by specific enzymes. Carbohydrate Research 1994, 255:285-293.
28. Ellman G. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 1959, 82:70-77.
29. Kruger N.J. The Bradford method for protein quantitation. The protein protocols handbook 2002, 15-21. Humana Press Inc., Totowa. J.M. Walker (Ed.).
30. Kennett E.C., Rees M.D., Malle E., Hammer A., Whitelock J.M., Davies M.J. Peroxynitrite modifies the structure and function of the extracellular matrix proteoglycan perlecan by reaction with both the protein core and the heparin sulfate chains. Free Radical Biology and Medicine 2010, 49:282-293.
31. Cakatay U., Kayali R., Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clinical and Experimental Medicine 2008, 8:51-57.
32. Pandey K.B., Mehdi M.M., Maurya P.K., Rizvi S.I. Plasma protein oxidation and its correlation with antioxidant potential during human aging. Disease Markers 2010, 29:31-36.
33. Voss P., Siems W. Clinical oxidation parameters of ageing. Free Radical Research 2006, 40:1339-1349.
34. Maggio M., Basaria S., Ceda G.P., Ble A., Ling S.M., Bandinelli S., Valenti G., Ferrucci L. The relationship between testosterone and molecular markers of inflammation in older men. Journal of Endocrinological Investigation 2005, 28:116-119.
35. Vasto S., Candor G., Balistreri C.R., Caruso M., Colonna-Romano G., Grimaldi M.P., Listi F., Nuzzo D., Lio D., Caruso C. Inflammatory networks in ageing, age-related diseases and longevity. Mechanisms of Ageing and Development 2007, 128:83-91.
36. Jha R., Rizvi S.I. Carbonyl formation in erythrocyte membrane proteins during ageing in humans. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia Univerzita Palackého v Olomouci 2011, 155:1-4.
37. Malemud C.J., Islam N., Haqqi T.M. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 2003, 174:34-48.
38. Kennett E.C., Davies M.J. Degradation of extracellular matrix by peroxynitrite/peroxynitrous acid. Free Radical Biology and Medicine 2008, 45:716-725.
39. Duan J., Kasper D.L. Oxidative depolymerization of polysaccharides by reactive oxygen/nitrogen species. Glycobiology 2011, 21:401-409.
40. Szweda P.A., Friguet B., Szweda L.I. Proteolysis, free radicals, and ageing. Free Radical Biology and Medicine 2002, 33:29-36.
41. Levine R.L. Carbonyl modified proteins in cellular regulation, ageing, and disease. Free Radical Biology and Medicine 2002, 32:790-796.
42. Rees M.D., Kennett E.C., Whitelock J.M., Davies M.J. Oxidative damage to extracellular matrix and its role in human pathologies. Free Radical Biology and Medicine 2008, 44:1973-2001.
43. Dalal M., Semba R.D., Sun K., Crasto K., Varadhan R., Bandinelli S., Fink J.C., Guralnik J.M., Ferrucci L. Endogenous secretory receptor for advanced glycation end products and chronic kidney disease in the elderly population. American Journal of Nephrology 2011, 33:313-318.
44. e{open}-carboxymethyllysine in brain ageing, diabetes mellitus, and Alzheimer's disease. Free Radical Biology and Medicine 2004, 36:1241-1247.
45. Semba R.D., Beck J., Sun K., Egan J.M., Carlson O.D., Varadhan R., Ferrucci L. Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore longitudinal study of ageing. Journal of Nutrition, Health and Aging 2010, 14:507-513.
46. Luevano-Contreras C., Chapman-Novakofski K. Dietary advanced glycation end products and ageing. Nutrients 2010, 2:1247-1265.
47. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
48. Koyama H., Yamamoto H., Nishizawa Y. Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomarker Insights 2007, 2:331-339.
49. Katakami N., Matsushita M., Kaneto H., Matsuoka T-A., Sakamoto K., Nakatani Y., Ohtoshi K., Hayaishi-Okano R., Kosugi K., Hori M., Yamasaki Y. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005, 28:2716-2721.
50. Koyama H., Shoji T., Fukumoto S., Shinohara K., Shoji T., Emoto M., Mori K., Tahara H., Ishimura E., Kakiya R., Tabata T., Yamamoto H., Nishizawa Y. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:147-153.
51. Kobayashi M., Squires G.R., Mousa A., Tanzer M., Zukor D.J., Antoniou J., Feige U., poole A.R. Role of interleukin-1 and tumor necrosis factor a in matrix degradation of human osteoarthritic cartilage. Arthritis & Rheumatism 2005, 52:128-135.